Novelion Therapeutics Supports World Lipodystrophy Day
March 31 2018 - 6:00AM
VANCOUVER, British Columbia, March
31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.
(NASDAQ:NVLN), a biopharmaceutical company dedicated to developing
new standards of care for individuals living with rare diseases,
today recognizes World Lipodystrophy Day.
Chief Operating Officer Jeff Hackman said, "We are
honored to join together with the patient community in support of
World Lipodystrophy Day, with a goal of increasing awareness of
this serious rare disease. Awareness and education are important
initiatives which help recognition and diagnosis of the
disease."
Lipodystrophy is a group of rare diseases
characterized by a lack of fat tissue. In some patients, it is
genetic, and in others it may be acquired. It can be characterized
by a widespread lack of fat tissue under the skin (generalized
lipodystrophy) or limited lack of fat tissue (partial
lipodystrophy). This loss of fat tissue causes a deficit in the
hormone leptin, leading to some severe metabolic complications.
"We are passionate about providing support for
lipodystrophy patients and their caregivers, and we advocate
tirelessly to increase understanding of the disease and further
research into lipodystrophy. World Lipodystrophy Day is an
important initiative that increases public awareness to help us
achieve these goals on behalf of patients living with this serious
and often unknown disease," said Andra Stratton, president and
co-founder of Lipodystrophy United.
"The challenges that patients living with
lipodystrophy and their families face are significant. World
Lipodystrophy Day helps us to raise awareness and understanding so
that we can improve diagnosis and care for those affected by this
rare disease globally," said Naca Eulalia Perez de Tudela Cánovas,
president and founder of the international organization Association
of Families Affected by Lipodystrophies in Spain, Europe &
Latin America.
To learn more about lipodystrophy,
visit www.lipodystrophyunited.org, www.aelip.es,
or www.lipodystrophy.co.uk.
CONTACT:
Novelion Therapeutics Inc.
Amanda Murphy
Director, Investor Relations & Corporate
Communications
857-242-5024
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novelion Therapeutics Inc. via Globenewswire
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024